Enrollment completed ahead of schedule. The Company plans to announce topline data in Q1 2018 and file a Biologics License Application (BLA) next year. To strengthen the regulatory package for U.S. and EU, the Company is enrolling patients in an additional international Phase 3 study (RECOVER),

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to

The FOLOTYN (antifolate) and an HDAC inhibitor (romidepsin) combination was shown to achieve a 71% overall response rate (ORR) among PTCL patients. HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of clinical data for FOLOTYN ® (pralatrexate

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and

ROLONTIS™ (eflapegrastim): Phase 3 ADVANCE Pivotal study: Number of evaluable patients reduced to 400 from 580, per an amended Special Protocol Assessment (SPA) received from the FDA . ADVANCE study is 75% enrolled and the Company expects to complete enrollment in the second half of this year.

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to

ROLONTIS is currently in a pivotal clinical development program and is on track for Spectrum to file BLA next year. Eflapegrastim was more potent than pegfilgrastim at G-CSF equivalent doses in this neutropenic rat model. HENDERSON, Nev --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI),

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its

Encouraging results observed in patient with exon 20 insertion mutation treated with poziotinib on a compassionate basis. Phase 2 trial will evaluate Objective Response Rate (ORR) as the primary endpoint. Top-line results are expected before year-end.

ROLONTIS™ (eflapegrastim) pivotal program is on track for Spectrum to file BLA next year. Poziotinib study in non-small cell lung cancer patients with EGFR Exon 20 insertion mutations, being run in partnership with The University of Texas MD Anderson Cancer Center , is expected to yield results

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and

Pre-clinical results show poziotinib could potentially be effective in patients with non-small cell lung cancer with EGFR exon 20 mutations. Computational modeling suggests that due to its small size, poziotinib may overcome the steric hindrance of the drug binding pocket.

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the presentation of data from a case match control analysis of the PROPEL

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that scientists from MD Anderson Cancer Center will be presenting